Anti-spike nanobody-IFN-β conjugated exosomes
An exosome-based anti-SARS-CoV-2 formulation.
Potential treatment - pre-clinical evidence
Anti-spike nanobody-IFN-β conjugated exosomes are an COVID-19 formulation combining an anti-Spike (SARS-CoV-2) nanobody, interferon-β and an exosomal delivery platform (Lyu et al., 2022). Exosomes are a class of nano-sized cell-derived extracellular vesicles. They carry various types of natural or engineered cellular components or substances (Zhang et al., 2020). Interferon (IFN)-β is a polypeptide produced primarily by fibroblast. It has antiviral and antiproliferative properties facilitated by gene products whose transcription IFN-β regulates (Markowitz, 2007). Anti-spike nanobody-IFN-β conjugated exosomes were shown to inhibit SARS-CoV-2 pseudovirus infection and upregulate interferon-stimulated genes in vitro (Lyu et al., 2022).
Preventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN-β Conjugated Exosomes
Spike protein Cell-based therapy Novel compound In vitro Mixed substance Extracellular vesicles
|ACE2-expressing A549 cells; ACE2-expressing HEK-blue IFNα/β cells
The exosomal formulation displayed anti-SARS-CoV-2 activity in vitro.